Pharmalot… Pharmalittle… Good Morning
1 CommentBy Ed Silverman // April 26th, 2011 // 7:03 am
Hello, everyone. Another shiny day is unfolding on the Pharmalot corporate campus, where we have successfully begun hustling the short people off to the local school house. As for us, we have a busy day planned since we will host a webinar later about pharma ad agencies and procurement issues (look here). Meanwhile, here are some tidbits to get you started. Hope today is a productive one and see you soon…
Merck Hep C Drug Boosted Cure Rates In Trials: FDA (Bloomberg News)
Abbott Trilipix & Statin Combo Can Cause Heart Problems: FDA (Reuters)
Painkillers Make Antidepressants Less Effective: Study (The Globe & Mail)
Cardinal Health Pays $8M To Settle Kickback Claims (Kansas City Business Journal)
Mitsui Buys CMO Operations In China (Outsourcing Pharma)
Costello
On the Abbott/Trilipix story, there was never any evidence that combining the drug with a statin had any benfits, and all the advertising had to say so. It is not surprising that, yet again, the statin/fibrate combo appears to be adding risk with no reward.
But Abbott has deployed an enomrous amount of marketing trying to suggest otherwise.